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abstract: Aberrant expression of microRNAs (miRNAs), including miR-21, and alteration of their target genes stability have been
associated with cellular transformation and tumorigenesis. We investigated the expression, regulation and function of miR-21 in leiomyomas
which develop from myometrial cellular transformation. The results indicated that miR-21 is over-expressed in leiomyomas with speciﬁc
elevation during the secretory phase of the menstrual cycle and in women who received Depo-Provera and oral contraceptives, but
reduced due to GnRHa therapy (P , 0.05). Bioinformatic analysis of microarray gene expression proﬁles previously obtained from the
above cohorts, and myometrial smooth muscle cells (MSMC) and leiomyoma smooth muscle cells (LSMC) treated with GnRHa, transforming
growth factor (TGF)-b and TGF-b receptor type II (TGF-bRII) antisense oligomer, indicated that a number of miR-21-predicted target genes
were co-expressed and differentially regulated in these cohorts. Gain- and loss-of-function of miR-21 in MSMC, LSMC, transformed LSMC
and leiomyosarcoma cell line (SKLM-S1) resulted in differential expression of many genes, including some of the miR-21-predicted/validated
target genes, PTEN, PDCD4 and E2F1, and TGF-bRII, in a cell-speciﬁc manner. Gain-of miR-21 function in MSMC and LSMC reduced TGF-
b-induced expression of ﬁbromodulin and TGF-b-induced factor (P , 0.05), and moderately altered the rate of cell growth and caspase-3/7
activity in these cells. We concluded that miR-21 is aberrantly expressed and hormonally regulated in leiomyomas where, through functional
interaction with ovarian steroids and the TGF-b signaling pathway, either directly or indirectly regulates a number of genes whose products
are critical in leiomyoma growth and regression as well as their potential cellular transformation.
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Introduction
microRNAs (miRNAs) have emerged as a key regulator of gene
expression stability (Engels and Hutvagner, 2006; Zeng, 2006; Fujita
and Iba, 2008; Selbach et al., 2008). Several thousand miRNAs have
been identiﬁed and/or predicted and the expression of a large
number of them has been proﬁled in various normal cells and
tissues and functionally associated with normal cellular activities such
as cell growth, differentiation and apoptosis (Engels and Hutvagner,
2006; Baek et al., 2008; Connolly et al., 2008; Fujita and Iba, 2008;
Ku and McManus, 2008; Selbach et al., 2008). Conversely, aberrant
expression of some miRNAs has been associated with a number of
disorders; more speciﬁcally, cancer, where they regulate gene
expression involved in cellular transformation and tumorigenesis
(Calin and Croce, 2006a, b; Engels and Hutvagner, 2006; Zeng,
2006; Cho, 2007). Furthermore, the genes encoding a number of
miRNAs are located at chromosomal fragile sites and at regions of
cytogenetic abnormalities associated with cancers (Calin and Croce,
2006b). Functionally, miRNAsthrough base-pairing with complementary
sites at30-untranslated region’s(UTR)ofspeciﬁctarget genes cause their
translational repression, and in some cases, mRNA degradation.
Expression proﬁling has also identiﬁed a few hundred miRNAs
expressed in myometrium and leiomyomas with altered expression
of a number of them, including miR-21 in leiomyomas (Wang et al.,
2007; Marsh et al., 2008; Pan et al., 2008). Altered expression of
miR-21 has been reported in many tumors of various origins and func-
tionally predicted to target the expression of several hundred genes
whose products are involved in cellular proliferation, apoptosis,
migration, transformation and tumorigenesis (Corsten et al., 2007;
Iorio et al., 2007; Lui et al., 2007; Meng et al., 2007; Si et al., 2007;
Asangani et al., 2008; Chan et al., 2008; Dillhoff et al., 2008; Frankel
et al., 2008; Gabriely et al., 2008; Lu et al., 2008). Among the exper-
imentally validated genes targeted by miR-21 are phosphatase and
tensin homolog (PTEN), programmed cell death 4 (PDCD4),
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(TIMP3), Sprouty2 (SPRY2), tropomyosin 1 and maspin in a number
of cell types (Meng et al., 2007; Gabriely et al., 2008; Lu et al.,
2008; Sayed et al., 2008; Zhu et al., 2008). The expression of
miR-21 has also been reported to be regulated by ovarian steroids
in MSMC and LSMC, and in the MCF-7 breast cancer cell line (Pan
et al., 2008; Wickramasinghe et al., 2009).
In addition, leiomyomas when compared with myometrium are also
characterized by differential expression of a large number of genes,
with speciﬁc gene polymorphisms and non-random chromosomal
abnormalities (Ligon and Morton, 2001; Luo et al., 2005b; Al Hendy
and Salama, 2006; Denschlag et al., 2006; Villanova et al., 2006; Pan
et al., 2007). As such, altered expression of miRNAs, including
miR-21 in leiomyoma, may have a direct regulatory function on the
expression of speciﬁc target genes whose products play a key role
in cellular transformation and their subsequent growth and/or apop-
tosis (Pan et al., 2008; Peng et al., 2008). To provide further
support for regulatory function of miR-21 in leiomyoma, the present
study was designed to (i) examine the expression and hormonal
regulation of miR-21 in paired myometrium and leiomyomas and
(ii) through gain- and loss-of function determine the expression of
genes regulated by miR-21 in MSMC and transition into LSMC, trans-
formed LSMC (t-LSMC) and the human leiomyosarcoma cell line
SKLM. In addition, through bioinformatic data mining, we assessed
the proﬁle of miR-21-predicted target genes in these tissues, as well
as in LSMC and MSMC treated with GnRHa, transforming growth
factor (TGF)-b1 and TGF-b receptor type II (TGF-bRII) siRNA. We
also examined the inﬂuence of gain-of function of miR-21 on the
expression of genes downstream from TGF-b receptor signaling and
cell growth and apoptosis in these cells.
Materials and Methods
Tissues
Portions of matched leiomyoma and myometrium were collected from
premenopausal women (n ¼ 23) who were scheduled to undergo hyster-
ectomy for indications related to symptomatic leiomyomas. The patients’
age ranged from 27 to 49 years (median ¼ 38). Of these patients, 13 were
not taking any medications, including hormonal therapy for the previous
3 months prior to surgery; based on last menstrual period and endometrial
histology, they were from the mid-proliferative (n ¼ 7) and
early-mid-secretory (n ¼ 6) phases of the menstrual cycle. The hormonal
therapies administered to women for medical management of their symp-
tomatic leiomyomas included: GnRHa (n ¼ 4), Depo-Provera (n ¼ 3) and
oral contraceptives (OCPs) (n ¼ 3). All the leiomyomas used in this study
were 3–5 cm in diameter and were collected at the University of Florida
afﬁliated Shands Hospital with prior approval from the Institutional Review
Board. Immediately after collection, the tissues were snapped frozen and
kept in liquid nitrogen for further analysis, or used for isolation of smooth
muscle cells.
Isolation and culture of leiomyoma and
myometrial smooth muscle cells
Myometrial smooth muscle cells (MSMC) and leiomyoma smooth muscle
cells (LSMC) were isolated from small portions of matched leiomyoma and
myometrium from women who did not receive any hormonal therapies
(Chegini et al., 2002). The cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplement with 10% fetal bovine serum (FBS)
and until reaching conﬂuence with change of media every 2–3 days.
Prior to use, the cells were characterized using antibodies to a-smooth
muscle actin, desmin and vimentin. Spontaneously transformed LSMC
(t-LSMC) originally established in our laboratory (Pan et al., 2008) and a
human leiomyosarcoma cell line, SKLM-S1 (purchased from ATCC),
were also cultured in DMEM supplement with 10% FBS. All the supplies
for isolation and culturing of the cells were purchased from Sigma-Aldrich
(St Louis, MO, USA), Invitrogen (Carlsbad, CA, USA) and Fisher Scientiﬁc
(Atlanta, GA, USA).
Transfection with miR-21 oligonucleotides
On the basis of the type of experiments, MSMC, LSMC, t-LSMC and
SKLM-S1 were seeded at various densities in 96-, 24- and 6-well plates
and in 10 cm Petri dishes and cultured until reaching 70% conﬂuence. The
cells were washed and incubated in antibiotic-free media for 24 h. Prior
to large-scale transfection, the transfection condition was optimized using
cells cultured in 24-well plates in Opti-MEM I serum-reduced medium,
BLOCK-iT Fluorescent Oligo and Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s protocol. Following optimization, the cells were
transfected with 50 nM of 20-O-methoxyethyl (20-O-MOE) modiﬁed
pre-miR-21, anti-miR-21 and their respective negative controls (Ambion)
for 6 h. The media were removed and the cells were cultured with full
growth medium for 24, 48 and 72 h. Total RNA was isolated from these
cells and subjected to real-time PCR. On the basis of the result of miR-21
expression in transfected MSMC, LSMC, t-LSMC and SKLM-S1, all the
experiments were carried out for 48 h unless otherwise stated.
Bioinformatic analysis
The computational algorithms TargetScan (http://www.targetscan.org/)
and miRDB (http://mirdb.org) were utilized for selection of miR-21-
predicted target genes. The search results were downloaded to a local
database and ﬁltered using Microsoft Access. In addition, a few genes
experimentally validated as miR-21 targets in other cell types were ident-
iﬁed through PubMed search and added to the database (Supplementary
data, Table SI). Table SI consists of 265 genes utilized for data mining
and bioinformatic analysis throughout this study.
Through data mining, we searched for the expression of the 265 genes
in the microarray database previously collected from (i) paired leiomyoma
and myometrium from Caucasians and African Americans and from
women who received GnRHa therapy; (ii) LSMC and MSMC treated
with GnRHa (0.1 mM) for 2, 6 and 12 h; (iii) LSMC and MSMC treated
with TGF-b1 (2.5 ng/ml) for 2, 6 and 12 h; and (iv) LSMC and MSMC
treated with TGF-bRII antisense oligomer (1 mM) for 24 h and then
treated with TGF-b1 (2.5 ng/ml) for an additional 24 h (Luo et al.,
2005a, b; Pan et al., 2007). The normalized and transformed expression
values of 194 genes were commonly identiﬁed in these cohorts (all 265
were expressed in paired leiomyoma and myometrium from Caucasians
and African Americans), which were sorted based on a 1.5-fold change
cut-off (Supplementary data, Table SI) and analyzed by cluster and tree-
view. The gene list was also subject to functional analysis using the Ingenu-
ity Pathways Software (Ingenuity
w Systems, Redwood City, CA, USA).
Real-time quantitative RT–PCR
Using real-time PCR, the relative expression of miR-21 was determined in
paired leiomyoma and myometrium from the proliferative and secretory
phases of the menstrual cycle, from women who received GnRHa and
Depo-Provera or OCPs. Transfection efﬁciency of anti- and pre-miR-21 in
LSMC, MSMC, t-LSMC and SKLM was also determined using real-time
PCR. Total RNA was extracted from these tissues and cells using Trizol
(Invitrogen), and RNA quantity and quality were determined using an
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USA) and an Agilent Bio-Analyzer, respectively. Reverse transcription (RT)
was performed with the Taqman microRNA RT Kit (Applied Biosystems)
using a miR-21 stem-loop primer (Ambion). Each reaction was performed
on 10 ng or 1 mg of total RNA. Real-time PCR was carried out using
Taqman gene expression master mix and Taqman miRNA and/or gene
expression assays, respectively (Applied Biosystems). Reactions were incu-
bated for 10 min at 958C, followed by 40 cycles of 15 s at 958C, and for
1 min at 608C. Analysis of relative miRNA and mRNA expression was
performed using the DDCT method with U6 and 18s rRNA as endogenous
controls, respectively, according to the manufacturer’s guidelines.
Western blot analysis
Western blot analysis was carried out following gain- and loss-of function
of miR-21 in LSMC, MSMC, t-LSMC and SKLM. Total protein was isolated
from these cells using lysis buffer containing protease inhibitor, centrifuged
and the supernatants were collected; their total protein content was
determined using a conventional method as described previously (Luo
et al., 2006; Pan et al., 2007). Equal amounts of sample proteins (20 mg)
were subjected to SDS–PAGE, transferred onto polyvinylidene diﬂuoride
membranes, and following further processing, the blots were probed with
antibodies generated against a select number of miR-21 target genes;
including E2F1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), PTEN
(Santa Cruz), PDCD4 (Santa Cruz and Abcam, Cambridge, MA, USA)
and TGF-bRII (Santa Cruz Biotechnology and Abcam) at 1:200 and
1:500 (TGF-bRII) dilutions. The membranes were also probed with an
antibody generated against b actin (Sigma-Aldrich) at a 1:10 000 dilution
serving as a loading control. Blots were washed and exposed to
corresponding horseradish peroxidase-conjugated IgG; immunostained
proteins were visualized using enhanced chemiluminescence reagents
(Amersham-Pharmacia Biotech, Piscataway, NJ, USA), and band densities
were determined as described previously (Levens et al., 2005; Luo et al.,
2005a, 2006).
Inﬂuence of miR-21 gain-of function on
TGF-bRII downstream gene expression
MSMC, LSMC, t-LSMC and SKLM-S1 were cultured in 6-well plates and in
10 cm Petri dishes until reaching subconﬂuence. Following gain- and
loss-of-miR-21 function as described above, the cells were serum-starved
for 24 h and then treated with TGF-b1 (2.5 ng/ml) for 24 h. Total RNA
and protein were isolated from these cells and subjected to real-time
PCR and western blot analysis, respectively, to determine the expression
of ﬁbromodulin (FMOD) and TGF-b-induced factor (TGIF)—two known
targets of TGF-b regulatory function (Luo et al., 2005a, 2006; Levens
et al., 2005). Western blotting was carried out using antibodies generated
against FMOD and TGIF at 1:1000 dilution (Santa Cruz Biochemical) and
processed as described above.
Cell proliferation and caspase-3/7
production assay
MSMC, LSMC, t-LSMC and SKLM-S1 were cultured in 96-well plates at a
density of 5000 cells/well for 24 h, and washed and subjected to gain- and
loss-of function of miR-21 as described above. After 48 h of incubation,
the cells were subjected to Cell Titer 96 Aqueous Non-Radioactive
Cell Proliferation Assay (Promega, Madison, WI, USA) according to the
manufacturer’s protocol. The rate of absorbance was determined using
a multiplate reader and the results were presented as fold change when
compared with their respective untreated controls.
The cells with miR-21 gain- and loss-of functions were also treated with
100 ml of Caspase Glo 3/7 reagent according to the manufacturer’s
instructions (Promega). MSMC treated with 1 mM Staurosporine (Sigma)
for 24 h was used as a positive control according to the Caspase Glo
3/7 Assay Technical Bulletin. The caspase-3/7 activities were determined
using a multiplate reader and relative luminescence intensity was
presented as fold change when compared with untreated controls.
Gene expression microarray
Total RNA isolated from LSMC, MSMC, t-LSMC and SKLM-S1 with
miR-21 gain- and loss-of functions was subjected to large-scale gene
expression proﬁling. Following ampliﬁcation and second-strand cDNA syn-
thesis, 5 mg of puriﬁed cDNA was reverse transcribed using a high-yield
RNA transcript labeling kit (Ambion). The product was puriﬁed and
20 mg of cRNA (0.5 mg/ml) was fragmented, mixed with 300 ml of hybrid-
ization mixture and 200 ml of the mixture was hybridized to Human Ref-8
v3 Expression BeadChip (Illumina, Inc., San Diego, CA, USA), consisting of
24 526 oligonucleotide probe sets representing 18 630 transcripts. The
beads were processed after meeting recommended criteria for use of
the expression arrays according to the manufacturer’s protocol.
The expression values were background-subtracted, globally normalized
using BeadStudio version 1.5.1.3 (Illumina), and as recommended, the
expression values with a differential score of  13 were independently
removed from each cohort. Transformed gene expression values were
subjected to supervised assessments and differentially expressed genes
were selected based on P   0.05 [analysis of variance (ANOVA), Tukey
test] and a 1.5-fold change cut-off (Pan et al., 2007). Data presented in
Fig. 5 were derived from the gene expression values selected based on
two-way ANOVA, supervised assessments by removing gene expression
values  50 and sorted based on a 1.5-fold cut-off in MSMC with
miR-21 gain-of function divided to control. These values were subjected
to cluster and tree-view analysis and functional analysis using Ingenuity
Pathways Software (Ingenuity
w Systems).
Statistical analysis
Whenever appropriate, the results were reported as mean+SEM of at
least three experiments performed using different MSMC and LSMC prep-
arations from three different patients. Comparisons between two or
among multiple groups were made using paired t-test and ANOVA fol-
lowed by a Tukey’s honest signiﬁcant difference post hoc pairwise multiple
comparison, respectively, and P , 0.05 was considered statistically
signiﬁcant.
Results
This study consisted of three integrated parts aiming to analyze the
expression, regulation and functional signiﬁcance of miR-21 in myome-
trium and leiomyoma, their isolated smooth muscle cells, spon-
taneously transformed LSMC as well as a leiomyosarcoma cell line.
miR-21 expression is altered in leiomyomas
Microarray proﬁling identiﬁed the expression of a few hundred
miRNAs with altered expression of several of them, including
miR-21, in leiomyomas, LSMC, t-LSMC and SKLM-S1 when compared
with myometrium and MSMC (Wang et al., 2007; Marsh et al., 2008;
Pan et al., 2008). As part of continuation of this work and the ﬁrst aim
of the present study, we further assessed the expression and regu-
lation of miR-21 in paired leiomyoma and myometrium during the
menstrual cycle and in women who received hormonal therapies for
medical management of their symptomatic leiomyomas. As shown
in Fig. 1, miR-21 is expressed at elevated levels in leiomyomas when
miR-21 regulation and gene targets in leiomyoma 217compared with myometrium from both proliferative and secretory
phases of the menstrual cycle (P , 0.05), conﬁrming the above
studies. In addition, the relative expression of miR-21 in leiomyomas,
but not myometrium, was higher in women who received Depo-
Provera and OCPs and lower in women who received GnRHa
therapy (Fig. 1, P , 0.05). The pattern of miR-21 expression levels
determined by real-time PCR in these cohorts correlated with the
pattern obtained from microarray proﬁling, with the exception of a
moderate increase in miR-21 expression in leiomyomas from the
OCP group (data not shown).
miR-21-predicted target genes are expressed
and regulated by GnRHa therapy
As a continued part of the ﬁrst aim, we focused on the expression
proﬁle of genes predicted/validated as miR-21 targets (Supplementary
data, Table SI) in myometrium and leiomyoma. Utilizing the list of 265
genes predicted and/or validated as miR-21 targets (Supplementary
data, Table SI) through data mining of microarray data sets previously
obtained in: (i) paired leiomyomas and myometrium from Caucasians
and African Americans and women who received GnRHa therapy; (ii),
LSMC and MSMC treated with GnRHa (0.1 mM) or with TGF-b1
(2.5 ng/ml) for 2, 6 and 12 h; and (iii) LSMC and MSMC treated
with TGF-bRII siRNA (1 mM) for 24 h and then treated with
TGF-b1 (2.5 ng/ml) for an additional 24 h, we identiﬁed the
expression of 194 of these genes commonly expressed among the
cohorts with cluster and tree-view analyses shown in the Supplemen-
tary data, Figs S1–3. The number of genes differentially expressed
( 1.5-fold change cut-off) in leiomyomas when compared with myo-
metrium from Caucasians and African Americans (Supplementary
data, Fig. S1A), in women who received GnRHa therapy when com-
pared with the untreated group (Supplementary data, Fig. S1B), and
in MSMC and LSMC treated with GnRHa (Supplementary data, Fig.
S3A) is presented as part of the Supplementary Table SI. Noticeable
among the differentially expressed genes are PDCD4, PTEN,
SPRY1, E2F1, STAT3 and TGF-bRII, suggesting the possible regulation
of some of the miR-21 target genes by GnRHa. Pathway analysis
identiﬁed and mapped 21 functional networks among these genes,
with 15 networks containing a majority of the genes, including net-
works 1, 2 and 3 with network 1 having most of the TGF-b-related
genes (network 1 and merged networks 1, 2 and 3 are shown in
two ﬁgures in Supplementary Table SI). The biological functions of
the genes in these networks are shown in a bar graph (Supplementary
data, Table SI), which include regulation of cell growth and prolifer-
ation, cell death, connective tissue development and function, cell
assembly, transcriptional regulation, and cancer.
Experimental validation of miR-21
target genes
As a second part of the aim of this study, we focused on experimental
validation of a few miR-21 target genes in leiomyoma and myometrial
cells. To accomplish this, we isolated MSMC and LSMC (primary cul-
tures through third passage), and t-LSMC and SKLM-S1, and trans-
fected the cells with pre- and anti-miR-21 (gain-and loss-of
functions, respectively) for 24, 48 and 72 h. Prior to transfection,
the basal expression of miR-21 was determined in each cell type
and, as indicated, MSMC expressed a lower level of miR-21 when
compared with LSMC, t-LSMC and SKLM (Fig. 2A). As expected,
gain-of-miR-21 function signiﬁcantly increased, whereas loss-of func-
tion decreased the expression of miR-21, when compared with
scrambled-oligo-transfected cells after 48 h (P , 0.05; Fig. 2B) and
72 h (data not shown) of incubation. Since PTEN, PDCD4 and E2F1
have been experimentally validated as miR-21 targets in several cell
types, we next assessed whether gain- or loss-of function of miR-21
altered their expression and the expression of TGF-bRII in MSMC,
LSMC, t-LSMC and SKLM-S1. These cells expressed PTEN, PDCD4,
E2F1 and TGF-bRII mRNAs and proteins at varying levels (Figs 3
and 4) and gain- and loss-of-miR-21 function differentially altered
their expression in a cell-speciﬁc manner when compared with
scrambled-oligo-transfected controls (Figs 3 and 4; P , 0.05).
However, the level of E2F1 production in MSMC and LSMC, and
PDCD4 production in MSMC, LSMC, t-LSMC and SKLM-S1 were
very low with weak band intensity (data not shown). The degree of
miR-21 functional regulation of PTEN, PDCD4, E2F1 and TGF-bRII
expression in these cells is possibly due in part to differences in the
baseline expression of the genes, or cell-type-dependent action of
miR-21; i.e. more effective inhibition of TGF-bRII in SKLM-S1 and
MSMC, when compared with LSMC with least inhibition in t-LSMC.
miR-21 overall regulation of gene expression
in MSMC and LSMC
To further assess the overall regulatory function of miR-21 on MSMC,
LSMC, t-LSMC and SKLM gene expression, total RNA was isolated
from these cells (with gain- and loss-of function of miR-21) and sub-
jected to gene microarray analysis. Based on P   0.05 (ANOVA)
and a 1.5-fold change cut-off, the expression of 117, 807, 705 and
998 genes was altered (directly and/or indirectly) as a result of
Figure 1 Relative expression of miR-21 in paired leiomyoma (LYO)
and myometrium (MYO) from the proliferative (n ¼ 6) and secretory
(n ¼ 6) phases of the menstrual cycle, and in women who received
GnRHa therapy (GnRHa; n ¼ 3), Depo-Provera (n ¼ 4) and those
taking OCPs (n ¼ 3).
Lines indicate a signiﬁcant difference between LYO and corresponding MYO in
each cohort. Different letters indicate a signiﬁcant difference among treatments
(P , 0.05; paired t-test and ANOVA)
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respectively, when compared with scrambled-oligo-transfected con-
trols (Supplementary data, Table SIIA–D). Of these genes, the
expression of 83, 609, 434 and 702 genes was down-regulated and
of 34, 198, 271 and 296 genes was up-regulated in MSMC, LSMC,
t-LSMC and SKLM, respectively (Supplementary data, Table SIIA–
D). Loss-of function of miR-21 also altered the expression of a
number of genes, some displaying an inverse pattern of expression
when compared with cells with gain-of miR-21 function (Supplemental
data, Table SII). Cluster/tree-view analysis of 406 differentially regu-
lated genes in MSMC with gain-of miR-21 function versus control is
shown in Fig. 5 with the enlarged region showing several genes, includ-
ing TGF-bRII (TGFBR2), whose expression was altered in MSMC,
LSMC and SKLM-S1, and to a lesser extent in t-LSMC (Fig. 3).
Functional pathway analysis mapped several networks among the
genes targeted by gain-of function of miR-21 in MSMC, LSMC,
t-LSMC and SKLM-S1 (see ﬁgures embedded into Supplementary
Table SIIA–D, respectively; and network summary in Supplementary
Table SII). A majority of the focus genes function as transcriptional,
translational and signal transduction mediators, and in cell cycle regu-
lation, ECM turnover, cell–cell communication and metabolic activities
etc. (see bar graphs embedded into Supplementary Table SIIA–D).
The list of 15 genes, including TGFbRII, whose expression was com-
monly altered as a result of miR-21 gain-of function in MSMC, LSMC,
Figure 2 Relative level of miR-21 endogenous expression in
MSMC, LSMC, t-LSMC and SKLM-S1 (A) and following gain- and
loss- of function of miR-21 (B).
Cells were cultured and at 70% conﬂuence, were transfected with 20-O-MOE
miR-21 inhibitor (anti-miR-21), pre-miR-21 or their respective scrambled
control (Ctrl) oligonucleotides (50 nM) for 48 h. Total RNA was isolated
from these cells and the level of miR-21 expression was determined using real-
time PCR. The expression value in MSMC (A) and controls for each cohort
independently (B) was set at 1. Different letters or number of asterisks indicate
a signiﬁcant difference among cell types and treatments, respectively, when
compared with their respective controls (Ctrl) with P , 0.05 considered
signiﬁcant.
Figure 3 Western blot analysis of PTEN, E2F1 and TGF-bRII pro-
duction in MSMC, LSMC, t-LSMC and SKLM-S1 with gain- and
loss-of-function of miR-21.
Total cellular protein was isolated from cells transfected with 20-O-MOE
anti-miR-21 (A), pre-miR-21 (P) or their respective scrambled oligomer con-
trols (AC and PC) for 48 h and subjected to immunoblot analysis. Note con-
siderable changes in the level of production of PTEN in MSMC and LSMC;
E2F1 in t-LSMC and SKLM-S1; and TGF-bRII in MSMC, LSMC and SKLM-S1
(see densitometric analysis in Fig. 4) when compared with controls.
miR-21 regulation and gene targets in leiomyoma 219Figure 4 The level of (mean+SEM) expression of E2F1 (A and B), PTEN (C and D), TGF-bRII (E and F) and PDCD4 (G) mRNA (A, C, E and G)
and protein (B, D, and F) determined by real-time PCR and western blot analysis, respectively, in MSMC, LSMC, t-LSMC and SKLM with gain- and
loss-of-function of miR-21 as described in Fig. 3. Note considerable alterations in the level of gene expression in pre-mir-21 versus anti-mir-21 treated
cells when compared with scrambled oligomer-treated (Ctrl) cells. The basal expression of E2F1, PTEN and PDCD4 is shown in (H). The expression
values in MSMC (H) and in controls for other cohorts were independently set at 1 for each cell type. Different letters or number of asterisks indicate a
signiﬁcant difference among cell types (A–G) or genes analyzed (H), respectively, when compared with their respective controls (Ctrl) with P , 0.05
considered signiﬁcant.
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Additionally, of the 265 genes predicted/validated as miR-21 targets
(Supplementary data, Table SI), the expression of 9, 10, 31 and 10
genes, including TGF-bRII, was altered in MSMC, LSMC, t-LSMC
and SKLM-S1, respectively, as a result of miR-21 gain-of function (Sup-
plemental data, Table SIIF).
Regulation of miR-21-predicted target genes
by TGF-b and inﬂuence of gain-of function
of miR-21
Since TGF-bRII appeared to be a target of miR-21 regulatory function
(Figs 3 and 4), as a third aim of this study, we assessed whether the
expression of genes downstream from TGF-b receptor signaling is
altered as a result of miR-21 gain-of function. As illustrated in Fig. 6A–
C, 20-O-MOE modiﬁed pre-miR-21-transfected MSMC and LSMC (P)
treated with TGF-b1 (P-TGF) produced signiﬁcantly lower levels of
FMOD and transforming growth interacting factor (TGIF) when com-
pared with cells transfected with negative control oligo (PC) and PC
treated with TGF-b1 (PC-TGF) (Fig. 6; P , 0.05). We extended this
aimandassessedtheexpressionpatternofthegenespredicted/validated
as miR-21 targets (Supplementary data, Table SI) in microarray proﬁles
previously obtained from LSMC and MSMC treated with TGF-b
(2.5 ng/ml) for 2, 6 and 12 h, and cells treated with TGF-bRII antisense
siRNA for 24 h followed by TGF-b treatment. The data mining indicated
that35genesweredifferentiallyexpressedandalteredbyatleast1.5-fold
in MSMC and LSMC treated with TGF-b (Supplementary data, Fig. S2A)
and TGF-bRII siRNA (Supplementary data, Fig. S2B).
Figure 5 Cluster and tree-view analyses of 406 up- and down-regulated genes selected based on two-way ANOVA with a  1.5-fold change cut-off
in MSMC with gain-of miR-21 function/control in MSMC, LSMC, t-LSMC and SKLM-S1.
The cells were transfected with 20-O-MOE anti-miR-21(Anti), pre-miR-21 (Pre-mir) or their respective scrambled oligomers (Ctrl) for 48 h. Enlarged area shows the heat
map and the list of genes, including TGFBR2 (TGF-bRII), whose expression was altered in these cohorts. The lists of up- or down-regulated genes, the Ingenuity pathways
analysis and the biological function of the genes in MSMC, LSMC, t-LSMC and SKLM-S1 are presented in Supplementary Table SIIA–D, respectively.
miR-21 regulation and gene targets in leiomyoma 221miR-21 gain- and loss-of functions on cell
growth and caspase activity
Aberrant expression of miR-21 has been associated with alteration of
cell growth and apoptosis in various cell types. To follow up on the
functional signiﬁcance of miR-21, we determined the inﬂuence of
miR-21 gain- and loss-of functions on cell growth and apoptosis of
MSMC, LSMC, t-LSMC and SKLM-S1. The results indicated that
miR-21 gain- and loss-of functions have a moderate effect on the
rate of cell proliferation and caspase-3/7 activity, which occurred in
a cell-type-speciﬁc manner (Fig. 7, P , 0.05).
Discussion
Accumulated evidence has associated the aberrant expression of
many miRNAs, including miR-21, with various pathological disorders,
Figure 6 Gain-of function of miR-21 alters TGF-bRII and TGF-b-regulated genes.
MSMC andLSMCwere transfectedwith20-O-MOE pre-mir-21(P) or scrambledoligomercontrols(PC) for 48 h,and then treated withTGF-b1 (2.5 ng/ml) for24 h(P-TGF
andPC-TGF).TotalproteinisolatedfromthesecellswassubjectedtowesternblotanalysisofFMODandTGIF(A)andtheirbanddensities(mean+SEM)arereportedin(B
and C), respectively. b-Actin was used as a loading control. The control (bars representing PC) band intensity values are independently set at 1 for each protein. Different
letters indicate a signiﬁcant difference among treatments when compared with their respective controls (Ctrl), with P , 0.05 considered signiﬁcant.
222 Pan et al.more speciﬁcally cancers, and with the regulation of the expression of
speciﬁc genes involved in various aspects of tumorigenesis, i.e. cellular
transformation, proliferation, apoptosis and migration (Si et al., 2007;
Asangani et al., 2008; Chan et al., 2008; Connolly et al., 2008; Dillhoff
et al., 2008; Fujita et al., 2008; Gabriely et al., 2008; Sayed et al., 2008;
Talotta et al., 2008; Zhu et al., 2008). In the present study, we con-
ﬁrmed that miR-21 is aberrantly expressed in leiomyomas when com-
pared with myometrium (Wang et al., 2007; Marsh et al., 2008; Pan
et al., 2008). We further demonstrated a speciﬁc increase in
expression of miR-21 in leiomyomas, but not in myometrium, during
the secretory phase of the menstrual cycle and in women who
received Depo-Provera and OCPs, with lower expression in women
who received GnRHa therapy. It was previously observed that
miR-21 is differentially regulated by ovarian steroids in MSMC and
LSMC, and this included an increase in expression of miR-21 following
medroxyprogesterone acetate treatment (Pan et al., 2008). Although
the in vitro condition does not reﬂect the complex in vivo milieu, these
results imply that miR-21 is hormonally regulated in leiomyomas,
potentially inﬂuencing the expression of genes targeted by miR-21.
Through data mining, a number of miR-21-predicted/validated
target genes, including PDCD4, PTEN, SPRY1, SPRY2, E2F1 and
TGFbRII were identiﬁed as differentially expressed in leiomyomas
Figure 7 Cell growth and apoptosis in response to miR-21 gain- and loss-of functions.
MSMC, LSMC, t-LSMC and SKLM were cultured and transfected with anti-miR21, pre-miR-21 or their respective scrambled oligomer (Ctrl) for 48 h and the rate of
growth (A) and caspase-3/7 activity (B) were determined. Bar graphs (mean+SEM) show that gain-of function of miR-21 (pre-mir-21) in LSMC and SKLM moderately
increased the rate of cell growth and reduced caspase-3/7 activities, when compared with loss-of-function of miR-21 (anti-mir21) and Ctrl, respectively. The control
values are set at 1 independently for each group. Different letters indicate a signiﬁcant difference among cell types and treatments, respectively, when compared with
their respective controls (Ctrl) with P , 0.05 considered signiﬁcant.
miR-21 regulation and gene targets in leiomyoma 223when compared with myometrium from African Americans and Cau-
casians, and from patients who received GnRHa therapy. The
co-expression and ethnic and hormonal regulation of miR-21 and pre-
dicted target genes in leiomyomas imply their potential functional
interactions. As such, using isolated MSMC and LSMC as well as
t-LSMC and SKLM-S1 with gain- and loss-of function of miR-21
revealed that a number of genes, including some of miR-21-predicted
targets are potentially regulated by miR-21. However, there was a
considerable difference in the number and types of genes targeted
by miR-21 gain-of function among these cells, which could be due
to variation in the level of their endogenous miR-21 expression, or
the degree of cellular transformation (benign versus cancerous as in
LSMC versus t-LSMC and SKLM-S1). Since altered expression of
miR-21 has been associated with cellular transformation and tumori-
genesis (Cho, 2007; Connolly et al., 2008), and miR-21 differentially
regulates speciﬁc genes in a cell-type-based manner, miR-21 could
inﬂuence cellular events necessary for transformation of myometrial
cells into leiomyomas and further into leiomyosarcoma. Since
TGF-b plays a central role in pathogenesis of leiomyoma and
miR-21 appeared to regulate TGF-bRII expression, we extended
our investigation and through data mining we identiﬁed that a
number of miR-21-predicted/validated target genes differentially
expressed in MSMC and LSMC treated with TGF-b and TGF-bRII
antisense oligomer. Our preliminary results have also indicate that
TGF-b regulates the expression of miR-21 in MSMC and LSMC;
these results, in combination with the ﬁnding of our study, suggest a
direct and/or indirect regulatory interaction between TGF-b and
miR-21 in leiomyoma cells.
The biological signiﬁcance of regulatory interactions between
TGF-b and miR-21 and their target genes, PTEN, E2F1, PDCD4
and TGF-bRII, may lie in their functions in various cellular activities
critical to the outcome of tumorigenesis and tissue ﬁbrosis, including
in leiomyomas (Chegini, 2005; Luo et al., 2005a; Luo et al., 2006).
However, miR-21 differentially regulated the expression of PDCD4,
PTEN, E2F1 and TGF-bRII in MSMC, LSMC, t-LSMC and SKLM,
which could be either due to variations in basal endogenous
expression of these genes, or a cell-type-dependent action of
miR-21. As such, a feedback regulatory mechanism between
miR-21 and these genes, speciﬁcally TGF-b, may result in balancing
their different functions in a cell- and tissue-dependent context (i.e.
inﬂammatory response, cell growth regulation and tissue turnover),
leading to either cellular transformation and tumorigenesis, tissue
ﬁbrosis or tumor regression (Fig. 8). Although the TGF-b system is
well recognized as a key regulator of establishment and progression
of tissue ﬁbrosis, up-regulation of miR-21 has also been observed
in several ﬁbrotic disorders over-expressing TGF-b, including
cardiac hypertrophy, vascular walls balloon injury and neointimal
lesion (for review, see Krichevsky and Gabriely, 2009). However,
controversies exist regarding miR-21 functional regulation of cellular
events, and gene expression changes leading to tissue ﬁbrosis. Inhi-
bition of miR-21 reduced hypertrophy of cardiomyocytes and neoin-
tima formation, but resulted in cardiac cellular hypertrophy;
conversely, over-expression of miR-21 in cardiomyocytes altered
the expression of sets of genes and resulted in the development of
cellular hypertrophy (Thum et al., 2008; Krichevsky and Gabriely,
2009).
miR-21 has also been shown to regulate cellular dedifferentiation,
and in cell lines with low or undetectable expression of miR-21,
their differentiation resulted in increased miR-21 expression (Kri-
chevsky and Gabriely, 2009). As such, the cell-speciﬁc function of
miR-21 on PTEN, E2F1, PDCD4 and TGF-bRII expression in
MSMC, LSMC, t-LSMC and SKLM-S1, representing various stages of
progression from normal to benign, transformed and sarcoma, and dif-
ferentiated versus undifferentiated status, may reﬂect the diverse
actions of miR-21, including crosstalk with other miRNAs and target
gene products. PDCD4 acts as a tumor suppressor and decreases
benign and malignant tumor progression, whereas E2F1 acts as an
oncogene or a tumor suppressor regulating cell cycle progression
and apoptosis, depending on cellular context. PTEN antagonizes the
action of phosphatidylinositol-triphosphate kinase (PI3K)-signaling
pathways and Akt-signaling cascades, which increase cellular survival
and proliferation. Previous studies have demonstrated that TGF-b
down-regulates the expression of PTEN in various cell lines,
whereas it increases PDCD4 expression, mediating apoptosis
through caspase activation (Zhang et al., 2006). Functional interactions
between miR-21 and TGF-b in vascular smooth muscle cells, where
TGF-b, acting in part through miR-21 regulation and Smad signaling,
down-regulated the expression of PDCD4 (Davis et al., 2008).
MSMC and LSMC with gain-of function of miR-21 treated with
TGF-b also expressed lower levels of FMOD and TGIF, two genes
known to be regulated by TGF-b (Levens et al., 2005; Luo et al.,
2005a), comparable to TGF-bRII antisense-treated cells. Such cell-
and gene-target-speciﬁc actions of miR-21 may be necessary since
the products of many of the genes targeted by miR-21 also regulate
the expression of other genes, i.e. TGF-b regulation of PTEN, E2F1
and PDCD4 (Hu et al., 2000; Hjelmeland et al., 2005; Garcia-Alvarez
et al., 2006; Bu et al., 2008; Chow et al., 2008; Davis et al., 2008;
Lacerte et al., 2008; Petrocca et al., 2008; Selbach et al., 2008;
Talotta et al., 2008). Consistent with the level of gene expression in
MSMC, LSMC, t-LSMC and SKLM-S1 with gain- and loss-of miR-21
functions, proteomic analysis has also indicated that a single miRNA
repressed the production of many proteins; however, the level of
repression was relatively low, and miRNA actions occurred either
directly or indirectly through protein synthesis from thousands of
genes (Baek et al., 2008; Selbach et al., 2008).
The consequence of miR-21 functional regulation of TGF-bRII,
E2F1, PTEN and PDCD4 in leiomyoma cells could also involve cell
survival, while limiting their cellular transformation and tumorigenesis
when compared with t-LSMC and SKLM-S1. Aberrant expression of
miR-21 has been associated with alteration of cell proliferation,
migration, invasion and malignant transformation by targeting the
expression of select genes whose products are integral to these pro-
cesses (Meng et al., 2007; Si et al., 2007; Connolly et al., 2008; Lu
et al., 2008; Petrocca et al., 2008; Zhu et al., 2008). Pathway analysis
indicated that many of the genes targeted by miR-21 in MSMC, LSMC,
t-LSMC and SKLM-S1 are functionally involved in regulating the above
processes, as well as tissue development, connective tissue develop-
ment/function, cell assembly, cell cycle, cell death and metabolism.
However, gain- or loss-of function of miR-21 in MSMC, LSMC,
t-LSMC and SKLM-S1 had a limited effect on the rate of cell prolifer-
ation, while moderately affecting caspase activities. In several cancer
cell lines, inhibition of miR-21 decreased cell proliferation, migration
and invasion, and reduced PDCD4 production, while increasing
224 Pan et al.Figure 8 Schematic diagram describing the potential regulatory interactions between ovarian steroids, GnRHa, TGF-b and miR-21.
miR-21 and TGF-b are differentially regulated by ovarian steroids and GnRHa (Chegini et al., 2002; Pan et al., 2007; Luo and Chegini, 2008). TGF-b increases the
expression of miR-21 which suppresses the expression of TGF-bRII, resulting in reduced TGF-b receptor-mediated signaling. Regression of TGF-bRII by miR-21
either directly or indirectly alters TGF-b-induced miR-21 through a feedback mechanism, leading to differential expression of PTEN, E2F1 and PDCD4 and other
miR-21 target genes. As such, altered expression of miR-21, TGF-b, TGF-bRII, PTEN, E2F1 and PDCD4 could then alter the balance between the rate of cell
growth and apoptosis, inﬂammatory reaction and extracellular matrix accumulation, resulting in leiomyoma growth and regression, or mediate myometrial and leiomyoma
cellular transformation. Using Ingenuity pathway analysis provided a functional network among TGF-bRII-, PTEN-, E2F1- and PDCD4-mediated actions, which include
interactions with other gene products and signaling pathways (i.e. Smad, AKT, JUK, NFkb, cbp/p300, VEGF, 14-3-3 and proteasome) that regulate the above cellular
processes.
miR-21 regulation and gene targets in leiomyoma 225PTEN and matrix metalloproteinases 2 and 9 (Corsten et al., 2007;
Meng et al., 2007; Asangani et al., 2008; Frankel et al., 2008; Lu
et al., 2008; Zhu et al., 2008); we expected a similar trend at least
in t-LSMC and SKLM-S1 with miR-21 gain-of function. The reason
for differences in miR-21 action on the rate of cell proliferation/
caspase activities could be due to cell type speciﬁcity and/or the
extent of alteration of genes functionally regulating cell cycle pro-
gression and apoptosis. Additionally, it has been reported that NFIB,
a target of miR-21 regulatory function, binds to the miR-21 promoter
and negatively regulates its expression—a double-negative feedback
regulation considered to sustain miR-21 expression (Fujita et al.,
2008). As such, miR-21 functional regulation of TGF-bRII, E2F1,
PTEN and PDCD4 in leiomyoma cells could serve in mediating cell
survival, while limiting cellular transformation and tumorigenesis
when compared with t-LSMC and SKLM.
In summary, we provided further evidence that miR-21 is over-
expressed in leiomyomas when compared with myometrium in a men-
strual cycle-dependent manner, with altered expression in women
who received GnRHa, Depo-Provera and OCPs. More speciﬁcally,
we identiﬁed a number of genes as potential targets of miR-21 via
direct and/or indirect actions, including PDCD4, E2F1, PTEN and
TGF-bRII in MSMC, LSMC, t-LSMS and SKLM-S1, with potential regu-
lation by GnRHa and TGF-b in these cells. Functionally, miR-21 had a
moderate inﬂuence on the rate of proliferation and apoptosis of these
cells, but down-regulated the expression of TGF-b downstream target
genes. On the basis of our previous and present results, we propose a
feedback regulatory interaction between miR-21, TGF-b and ovarian
steroids, necessary to balance their different functions in a cell- and
tissue-dependent context, inﬂuencing events such as inﬂammatory
response, cell growth regulation and tissue turnover, leading either
to cellular transformation and tumorigenesis, or tissue ﬁbrosis
(Fig. 8). Although the goal of this study was to better understand
the regulatory function of miR-21 in leiomyomas, future investigation
is required to address the direct interaction of miR-21 with
TGF-bRII 30-UTR and with other miR-21 target genes, as well as
the biological signiﬁcance of other aberrantly expressed miRNAs in
leiomyoma and transformation into leiomyosarcoma.
Supplementary data
Supplementarydataareavailableathttp://molehr.oxfordjournals.org/.
Funding
This work was supported by grants RO1HD37432 and RO1HD58664
(N.C.) and RO3HD58779 (X.L.) from the National Institutes of Health.
References
Al Hendy A, Salama SA. Catechol-O-methyltransferase polymorphism is
associated with increased uterine leiomyoma risk in different ethnic
groups. J Soc Gynecol Investig 2006;13:136–144.
Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S,
Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally
downregulates tumor suppressor Pdcd4 and stimulates invasion,
intravasation and metastasis in colorectal cancer. Oncogene 2008;
27:2128–2136.
Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of
microRNAs on protein output. Nature 2008;455:64–71.
Bu S, Kapanadze B, Hsu T, Trojanowska M. Opposite effects of
dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on
transforming growth factor-beta/Smad signaling are mediated through the
PTEN/PPM1A-dependent pathway. JB i o lC h e m2008;283:19593–19602.
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev
Cancer 2006a;6:857–866.
Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in
cancer cells. Oncogene 2006b;25:6202–6210.
Chan SH, Wu CW, Li AF, Chi CW, Lin WC. miR-21 microRNA
expression in human gastric carcinomas and its clinical association.
Anticancer Res 2008;28:907–911.
Chegini N. Gene expression and hormonal response. In: Brosens I (ed).
Uterine Leiomyomata:Pathogenesis and Management. London: Taylor &
Francis Group, 2005, 41–67.
Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues,
’add-back’ steroid therapy, antiestrogen and antiprogestins on
leiomyoma and myometrial smooth muscle cell growth and transforming
growth factor-beta expression. Mol Hum Reprod 2002;8:1071–1078.
Cho WC. OncomiRs: the discovery and progress of microRNAs in
cancers. Mol Cancer 2007;6:60.
Chow JY, Cabral JA, Chang J, Carethers JM. TGFbeta modulates PTEN
expression independently of SMAD signaling for growth proliferation
in colon cancer cells. Cancer Biol Ther 2008;7:1694–1699.
Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC,
Slagle BL, Rogler LE, Zavolan M, Tuschl T, Rogler CE. Elevated
expression of the miR-17-92 polycistron and miR-21 in
hepadnavirus-associated hepatocellular carcinoma contributes to the
malignant phenotype. Am J Pathol 2008;173:856–864.
Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K.
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays
synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in
human gliomas. Cancer Res 2007;67:8994–9000.
Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control
DROSHA-mediated microRNA maturation. Nature 2008;454:56–61.
Denschlag D, Bentz EK, Heﬂer L, Pietrowski D, Zeillinger R, Tempfer C,
Tong D. Genotype distribution of estrogen receptor-alpha,
catechol-O-methyltransferase, and cytochrome P450 17 gene
polymorphisms in Caucasian women with uterine leiomyomas. Fertil
Steril 2006;85:462–467.
Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is
Overexpressed in Pancreatic Cancer and a Potential Predictor of
Survival. J Gastrointest Surg 2008;12:2171–2176.
Engels BM, Hutvagner G. Principles and effects of microRNA-mediated
post-transcriptional gene regulation. Oncogene 2006;25:6163–6169.
Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH.
Programmed cell death 4 (PDCD4) is an important functional target of
the microRNA miR-21 in breast cancer cells. J Biol Chem 2008;
283:1026–1033.
Fujita S, Iba H. Putative promoter regions of miRNA genes involved in
evolutionarily conserved regulatory systems among vertebrates.
Bioinformatics 2008;24:303–308.
Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, Iba H.
miR-21 Gene expression triggered by AP-1 is sustained through a
double-negative feedback mechanism. J Mol Biol 2008;378:492–504.
Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS,
Krichevsky AM. MicroRNA 21 promotes glioma invasion by targeting
matrix metalloproteinase regulators. Mol Cell Biol 2008;28:5369–5380.
Garcia-Alvarez J, Ramirez R, Checa M, Nuttall RK, Sampieri CL,
Edwards DR, Selman M, Pardo A. Tissue inhibitor of
metalloproteinase-3 is up-regulated by transforming growth
226 Pan et al.factor-beta1 in vitro and expressed in ﬁbroblastic foci in vivo in
idiopathic pulmonary ﬁbrosis. Exp Lung Res 2006;32:201–214.
Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF,
Kontos CD, Rich JN. Loss of phosphatase and tensin homologue
increases transforming growth factor beta-mediated invasion with
enhanced SMAD3 transcriptional activity. Cancer Res 2005;
65:11276–11281.
Hu X, Cress WD, Zhong Q, Zuckerman KS. Transforming growth factor
beta inhibits the phosphorylation of pRB at multiple serine/threonine
sites and differentially regulates the formation of pRB family-E2F
complexes in human myeloid leukemia cells. Biochem Biophys Res
Commun 2000;276:930–939.
Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C,
Volinia S, Liu CG, Alder H et al. MicroRNA signatures in human ovarian
cancer. Cancer Res 2007;67:8699–8707.
Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol
Med 2009;13:39–53.
Ku G, McManus MT. Behind the scenes of a small RNA gene-silencing
pathway. Hum Gene Ther 2008;19:17–26.
Lacerte A, Korah J, Roy M, Yang XJ, Lemay S, Lebrun JJ. Transforming
growth factor-beta inhibits telomerase through SMAD3 and E2F
transcription factors. Cell Signal 2008;20:50–59.
LevensE,Luo X, Ding L, Williams RS,Chegini N. Fibromodulin is expressed
in leiomyoma and myometrium and regulated by gonadotropin-releasing
hormone analogue therapy and TGF-beta through Smad and
MAPK-mediated signalling. Mol Hum Reprod 2005;11:489–494.
Ligon AH, Morton CC. Leiomyomata: heritability and cytogenetic studies.
Hum Reprod Update 2001;7:8–14.
Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y.
MicroRNA-21 promotes cell transformation by targeting the
programmed cell death 4 gene. Oncogene 2008;27:4373–4379.
Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel
small RNAs in human cervical cancer. Cancer Res 2007;67:6031–6043.
Luo X, Chegini N. The expression and potential regulatory function of
microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med
2008;26:500–514.
Luo X, Ding L, Xu J, Chegini N. Gene expression proﬁling of leiomyoma
and myometrial smooth muscle cells in response to transforming
growth factor-beta. Endocrinology 2005a;146:1097–1118.
Luo X, Ding L, Xu J, Williams RS, Chegini N. Leiomyoma and myometrial
gene expression proﬁles and their responses to gonadotropin-releasing
hormone analog therapy. Endocrinology 2005b;146:1074–1096.
Luo X, Ding L, Chegini N. CCNs, ﬁbulin-1C and S100A4 expression in
leiomyoma and myometrium: inverse association with TGF-beta and
regulation by TGF-beta in leiomyoma and myometrial smooth muscle
cells. Mol Hum Reprod 2006;12:245–256.
Marsh EE, Lin Z, Yin P, Milad M, Chakravarti D, Bulun SE. Differential
expression of microRNA species in human uterine leiomyoma versus
normal myometrium. Fertil Steril 2008;89:1771–1776.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T.
MicroRNA-21 regulates expression of the PTEN tumor suppressor
gene in human hepatocellular cancer. Gastroenterology 2007;
133:647–658.
Pan Q, Luo X, Chegini N. Genomic and proteomic proﬁling I: leiomyomas
in African Americans and Caucasians. Reprod Biol Endocrinol 2007;5:34.
Pan Q, Luo X, Chegini N. Differential expression of microRNAs in
myometrium and leiomyomas and regulation by ovarian steroids. J Cell
Mol Med 2008;12:227–240.
Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, Wei JJ. Antiproliferative
effects by Let-7 repression of high-mobility group A2 in uterine
leiomyoma. Mol Cancer Res 2008;6:663–673.
Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de M I,
Iliopoulos D, Pilozzi E, Liu CG, Negrini M et al. E2F1-regulated
microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis
in gastric cancer. Cancer Cell 2008;13:272–286.
Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, Yan L,
Malhotra A, Vatner D, Abdellatif M. MicroRNA-21 targets Sprouty2
and promotes cellular outgrowths. Mol Biol Cell 2008;19:3272–3282.
Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R,
Rajewsky N. Widespread changes in protein synthesis induced by
microRNAs. Nature 2008;455:58–63.
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor
growth. Oncogene 2007;26:2799–2803.
Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G,
D’Esposito M, Di Lauro R, Verde P. An autoregulatory loop mediated
by miR-21 and PDCD4 controls the AP-1 activity in RAS
transformation. Oncogene 2008;28:73–84.
Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in
cardiac development and disease. Cardiovasc Res 2008;79:562–570.
Villanova FE, Andrade PM, Otsuka AY, Gomes MT, Leal ES, Castro RA,
Girao MJ, Nishimura E, Baracat EC, Silva ID. Estrogen receptor alpha
polymorphism and susceptibility to uterine leiomyoma. Steroids 2006;
71:960–965.
Wang T, Zhang X, Obijuru L, Laser J, Aris V, Lee P, Mittal K,
Soteropoulos P, Wei JJ. A micro-RNA signature associated with race,
tumor size, and target gene activity in human uterine leiomyomas.
Genes Chromosomes Cancer 2007;46:336–347.
Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y,
Klinge CM. Estradiol downregulates miR-21 expression and increases
miR-21 target gene expression in MCF-7 breast cancer cells. Nucl
Acids Res 2009;37:2584–2595.
Zeng Y. Principles of micro-RNA production and maturation. Oncogene
2006;25:6156–6162.
Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y,
Ideguchi H, Yamamoto K, Matsuhashi S. Involvement of programmed
cell death 4 in transforming growth factor-beta1-induced apoptosis in
human hepatocellular carcinoma. Oncogene 2006;25:6101–6112.
Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets
tumor suppressor genes in invasion and metastasis. Cell Res 2008;
18:350–359.
Submitted on May 11, 2009; resubmitted on October 19, 2009; accepted on
October 20, 2009
miR-21 regulation and gene targets in leiomyoma 227